Fate Therapeutics Forward-Looking Statements . The most common Fate Therapeutics Inc email format is first '.' last (ex. [email protected]) . Dive Brief: Fate Therapeutics on Thursday reported new results from two early-stage studies testing two types of experimental leukemia treatments that use natural killer cells, an emerging form of cancer immunotherapy. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. Sales ; Marketing ; . Founded in 2007, Fate Therapeutics is a clinical-stage biopharmaceutical company, that is developing . 2022 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 - 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL | PRIVACY About Us Our Mission The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its . Fate Therapeutics shares last traded at $26.80, with a volume of 2,317,211 shares trading hands. SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chief Technical Officer. 12278 Scripps Summit Dr. Report incorrect company information. SUITE 200, 3535 GENERAL ATOMICS COURT. Search San Diego, CA. SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or " Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 4, 2022 at 5:00 PM ET . Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]. 6201 15th Avenue. Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]. Fate Therapeutics Inc. (FATE) in the eye of market guru's. During the last month, 15 analysts gave the Fate Therapeutics Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating. . About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected] 2022 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 - 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL | PRIVACY About Us Our Mission View contact profiles from Fate Therapeutics. Print Page. SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Brian T. Powl has been appointed Chief Commercial Officer. SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage . Fate Therapeutics is a publicly-traded, clinical-stage, biopharmaceutical company mainly focusing on the development of first-in-class cellular immunotherapies. The company applies an in house iPSC and gene-editing platform to develop T- and natural killer cell therapies targeting blood . 92121. RSS News Feeds. View Kelly Griffis's business profile as Manager, Clinical Trial at Fate Therapeutics. Address: 3535 General Atomics Court, Suite 200, San Diego, California 92121, US Phone (858) 875-1800: Category: Biotechnology, Stem Cells, Pharmaceuticals, Science and Engineering, Stem Cell Modulators, Healthcare, Health Care, Ips Cells, Therapeutics, Ipscs: Web Rank: 1 Million: Keywords Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. The stock's 50 day moving average is $25.26 and its two-hundred day moving average is $36.40. All Fate Therapeutics Locations. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer . Fate Therapeutics has licensed intellectual property from MSK on which Dr. Sadelain is an inventor. Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive . Location of similar companies. The past year's Receivables Turnover was at 7.08. Prior to [] About Fate Therapeutics, Inc. 38,912 shares . The La Jolla, CA-based start-up founded in November 2007 has recruited an all-star team of scientists, clinicians, executives, and investors who together are pursuing the ultimate . San Diego, CA 92121. Download Library. In 2021, FATE's revenue was $55.85 million, an increase of 77.66% compared to the previous year's $31.43 million. $4,000,000. . Fate Therapeutics, Inc.Torrey Pines. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer question about prospects for Fate Therapeutics ( FATE -0.04%), a stock . ; Four of nine patients who received one Fate NK cell therapy showed evidence of a response, as did one of three who got a different type of NK cell therapy. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. How can I contact Fate Therapeutics' transfer agent? Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. 92121. Dec. 15, 2021 at 8:29 a.m. 2022 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGAL Posted: March 23, 2022. 12278 Scripps Summit Dr. Show all (2) Report incorrect company information. The Company is pioneering the development of off-the-shelf cell therapies using its proprietary iPSC product platform. Phone: 800-937-5449. www.amstock.com. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [ FATE ] 5. Open Map View. NAICS Code 325414,32541. Address. SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9 . 3535 General Atomics Ct. San Diego, CA. BY ROLE. Global Acute Lymphoblastic Leukemia (ALL) Market Spotlight 2019 Featuring Fate Therapeutics, Novartis, Ono Pharmaceutical - ResearchAndMarkets.com | Malvern Daily Record. Get Directions. SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies . Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Bob Valamehr. Thursday, May 7, 2020. Find the latest Fate Therapeutics, Inc. (FATE) stock quote, history, news and other vital information to help you with your stock trading and investing. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. Relationship of Reporting Person(s) to Issuer . Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics , Inc. . Leads by Industry . Get Fate Therapeutics Inc (FATE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Brian Powl is Chief Commercial Officer at Fate Therapeutics. We can divert our attention to . SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a conference Fate reported a loss of 48 cents per share in the first quarter of 2021, wider than the year-ago loss of 44 cents and the Zacks . [email protected]) being used 96.0% of the time. Fate Therapeutics upgraded to outperform from neutral at Wedbush, price target raised to $74 from $71. Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected] . FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues. Partners: Janssen Pharmaceuticals, Ono Pharma, Inscripta. About Fate Therapeutics, Inc. San Diego, CA. About Fate Therapeutics, Inc. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at [email protected] . Fate Therapeutics Inc Revenue: $10.00 Million | Employees: 376 | Industry: Biotechnology, Stem Cells, Pharmaceuticals . Fate Therapeutics (FATE) delivered earnings and revenue surprises of 1.72% and 64.34%, respectively, for the quarter ended September 2021. Posted by MarketBeat News on Jun 17th, 2022. The study involves up to 15 years post-infusion monitoring of subjects who have been exposed to lentivirus-mediated gene transfer in Fate Therapeutics clinical studies. Show More. Do the numbers hold clues to what lies ahead for the stock? Address. A Scripps Ranch life science lab and office campus has been leased to Fate Therapeutics for its corporate headquarters. Popular Searches: fate therapeutics inc. we have a process in place the begins with RocketReach and ends with huge contact lists for our sales team..it probably saves Feedtrail about 3 months of work in terms of lead gathering. Email Alerts. San Diego (HQ), CA. Fate Therapeutics, Inc is a clinicalstage biopharmaceutical company dedicated to the - development of first-in-class cellular immunotherapies for cancer and immune disorders. We use live photographers making your event fun with an open-air photo studio. Corporate Secretary 12278 Scripps Summit Drive San Diego, CA 92131 United States. The $1,220m strategic collaboration agreement signed in 2018 between Fate Therapeutics Fate Therapeutics is seeking a talented and highly motivated individual to oversee the aseptic cell-based manufacturing operations at Fate. Fun interactive photo studio with onsite printing at your corporate party, birthday parties, Bar Mitzvahs any event! Fate Therapeutics Inc - FATE stock news. IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell. Upon withdrawal or completion of the parent interventional study, the study site will contact the subject/healthcare provider/legal guardian annually. Total: $4,000,000.00. SIC Code 28,283. finance.yahoo.com - May 9 at 12:11 PM. Photo courtesy of JLL. 40 licensing and asset acquisition deals involving ALL drugs during 2014-19. Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE ) and Century Therapeutics Inc (NASDAQ: IPSC ), an analyst at BofA Securities said in a note on Tuesday.The Biopharma Analyst: Tazeen Ahmad has a Buy rating and . Fate Therapeutics Forward-Looking Statements . June 30, 2022 16:01 ET | Source: Fate Therapeutics, Inc. SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated . Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference. Prior to joining Fate, Mr. Powl most recently served as Senior Vice President, Commercial Development & Marketing at MEI Pharma, Inc., where he led the commercialization efforts of a late-stage small molecule program in B-cell malignancies across marketing, sales, market access and commercial operations. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications. [email protected]) and first '.' last_initial (ex. Discover the latest ERP, HCM, CRM, Procurement software purchases and digital transformation initiatives being undertaken by Fate Therapeutics, Inc. and its business and technology executives The company is based in Torrey Pines but plans to renovate Scripps Northridge Corporate Center, 12278 Scripps . Halozyme Therapeutics currently has a consensus target price of $53.20, suggesting a potential upside of 23.41%. United States. Do the numbers hold clues to what lies ahead for the stock? Fate Therapeutics Receivables Turnover is projected to slightly decrease based on the last few years of reporting. ET by Tonya Garcia. Posted by admin on Jun 17th, 2022. . About Fate Therapeutics, Inc. About Fate Therapeutics, Inc. While some stem cell companies strive to develop neatly packaged products for specific medical niches, and some aim to supply research tools others will use, Fate Therapeutics is planning to do all that and more. Get Verified Emails for Fate Therapeutics Inc Employees. . Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B . American Stock Transfer & Trust Company, LLC. Reporting Owner Name / Address: Relationships: Director: 10% Owner: Officer: Other: Agarwal Shefali C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO, CA 92131: X: Share. The company's pipeline includes various off-the-shelf, iPSC-derived cellular immunotherapies for the treatment of several hematological malignancies and advanced solid tumors. Printed Materials. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. Brooklyn, NY 11219. Ticker NASDAQ: FATE. Fate Therapeutics has licensed intellectual property from MSK on which Dr. Sadelain is an inventor. As an integral part of the Manufacturing Team, this role is responsible for providing leadership and direction in the production of drug products for all phases of . Mr. Powl brings to Fate Therapeutics extensive commercial leadership experience in hematologic malignancies . Contact About Us 2022 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 - 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL | PRIVACY Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Address: 3535 General Atomics Ct Ste 200 San Diego, CA, 92121-1140 United States See other locations Phone: (858) 875-1800 Website: www.fatetherapeutics.com The Company has established a . Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The company traded as high as $20.87 and last traded at $20.77. Get Fate Therapeutics Inc (FATE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. SUITE 200, 3535 GENERAL ATOMICS COURT. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications. Address 3535 General Atomics Ct Ste 200; State California; City San Diego; Zip 92121-1140; Country US . About Fate Therapeutics, Inc. 2022 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 - 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL | PRIVACY About Us Our Mission Fate Therapeutics has a consensus target price of $80.36, suggesting a potential upside of 315.10%. San Diego, CA, US (HQ) 3535 General Atomics Ct. San Diego, CA, US. Fate Therapeutics also holds an exclusive license to other inventions of Dr. Jaenisch relating to iPSC technology including PCT/US2008/004516 with a priority date of April 7, 2007, which describes . Fate Therapeutics, Inc. ( NASDAQ:FATE - Get Rating )'s share price shot up 7.3% during trading on Friday . Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cell. Financial Statements. Company profile page for Fate Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information . 3535 General Atomics Court, Suite 200. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Halozyme Therapeutics. Fate Therapeutics has an office in San Diego. United States. The Company's immunooncology pipeline is comprised . Fate Therapeutics Office Locations. Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected] . While Fate Therapeutics (NASDAQ:FATE) shareholders have made 502% in 5 years, increasing losses might now be front of mind as stock sheds 15% this week. Shareholder Tools. Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. Analyze Fate Therapeutics Receivables Turnover. Brand your photos with your logo, and market your events! Find contact's direct phone number, email address, work history, and more. Full-Time. The company traded as high as $20.87 and . Fate Therapeutics, Inc. ( NASDAQ:FATE - Get Rating) shot up 7.3% on Friday . Contact Us; Advertisement . Dr. Plavsic brings over 20 years of broad technical excellence in global biopharmaceutical . Solutions . Losses were -$212.15 million, 22.4% more than in 2020. Top Companies . . FATE Fate Therapeutics Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). The official website for Fate Therapeutics is www.fatetherapeutics.com . The stock has a market capitalization of $2.59 billion, a PE ratio of -11.03 and a beta of 1.71. . Other common formats are first_initial last (ex. You can contact Fate Therapeutics, Inc.'s Board of Directors to provide comments, to report concerns, or to ask a question, at the following address. Scripps Northridge Center will be renovated for Fate Therapeutics. finance.yahoo.com - June 3 at 11:04 AM. You may submit your concern anonymously or confidentially by postal mail. Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders.